PROCEPT BioRobotics financials
$18.22+5.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.5M | $83.1M | $76.4M | $83.3M | $79.2M | $69.2M | $68.2M | $58.4M | $53.4M | $44.5M | $43.6M | $35.1M |
| Gross profit | $62.4M | $53.9M | $46.3M | $54.0M | $51.7M | $44.2M | $43.7M | $36.9M | $31.5M | $25.0M | $21.3M | $18.9M |
| Gross margin | 66.0% | 64.9% | 60.6% | 64.8% | 65.4% | 63.9% | 64.0% | 63.2% | 59.0% | 56.2% | 48.8% | 53.8% |
| Operating income | -$27.4M | -$32.6M | -$31.0M | -$23.2M | -$22.2M | -$27.4M | -$19.7M | -$22.4M | -$26.8M | -$27.6M | -$29.6M | -$25.6M |
| Net income | -$26.9M | -$31.6M | -$29.8M | -$21.4M | -$19.6M | -$24.7M | -$18.9M | -$21.0M | -$25.6M | -$26.0M | -$27.5M | -$24.6M |
| Net margin | −28.4% | −38.1% | −39.1% | −25.7% | −24.7% | −35.8% | −27.6% | −35.9% | −48.0% | −58.3% | −63.1% | −70.1% |
| Diluted EPS | $-0.47 | $-0.56 | $-0.53 | $-0.38 | $-0.35 | $-0.45 | $-0.35 | $-0.40 | $-0.50 | $-0.51 | $-0.54 | $-0.51 |
| EBITDA | -$25.4M | -$30.9M | -$29.3M | -$21.6M | -$20.6M | -$26.0M | -$18.3M | -$21.1M | -$25.6M | -$26.5M | -$29.6M | -$24.6M |
| Operating cash flow | -$19.3M | -$38.1M | -$10.3M | -$6.6M | -$15.0M | -$17.0M | -$32.4M | -$18.8M | -$15.7M | -$32.3M | -$24.8M | -$18.9M |
| Free cash flow | -$22.2M | -$41.0M | -$12.2M | -$9.5M | -$17.8M | -$18.8M | -$33.6M | -$19.0M | -$16.8M | -$34.2M | -$33.5M | -$24.7M |
| Diluted shares | 57.1M | 56.5M | 56.1M | 55.7M | 55.4M | 54.9M | 53.9M | 52.0M | 51.6M | 51.0M | 50.5M | 48.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $227.9M | $245.6M | $286.5M | $294.3M | $302.7M | $316.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $51.7M | $51.7M | $51.6M | $51.6M | $51.5M | $51.5M |
| Total assets | $479.4M | $487.1M | $508.1M | $511.5M | $513.1M | $519.4M |
| Total liabilities | $139.3M | $139.4M | $142.2M | $131.3M | $127.3M | $130.2M |
| Shareholders' equity | $340.1M | $347.7M | $365.9M | $380.3M | $385.8M | $389.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology